Product logins

Find logins to all Clarivate products below.


The Company Franchise Analysis (CFA) provides a comprehensive evaluation of the franchise, including benchmarking, strategic insights, and an overview of marketed products. It highlights key market drivers and offers a detailed pipeline and sales analysis, along with information on deals and significant events. This profile aims to deliver a thorough understanding of the market dynamics and the strategic positioning of the franchise’s drugs.

Related Market Assessment Reports

Report
Acute Lymphoblastic Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The acute lymphoblastic leukemia (ALL) therapy market is entering a dynamic period of growth driven by the introduction of targeted agents and nextgeneration cell therapies. Widely used…
Report
Paroxysmal Nocturnal Hemoglobinuria – Unmet Need – Unmet Need – Paroxysomal Nocturnal Hemoglobinuria (US/EU)
The treatment landscape for paroxysmal nocturnal hemoglobinuria (PNH) has shifted dramatically in the past decade, moving beyond supportive care to transformative complement inhibition therapies…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) therapy market is rapidly evolving as novel agents provide alternatives to conventional chemoimmunotherapy regimens. This…
Report
Multiple Myeloma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment of multiple myeloma is becoming increasingly complex. Sanofi’s Sarclisa received a label expansion for the first-line treatment of autologous stem-cell transplantation-ineligible…
Report
Acute Myeloid Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)
Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new…